Estrogen Receptor Positive Advanced Breast Cancer Therapeutics
1. Inluriyo patent expiration
Treatment: Treatment of adults with er-positive, her2-negative esr1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10654866 | ELI LILLY | Selective Estrogen Receptor Degraders |
Jul, 2039
(13 years from now) | |
| US11117902 | ELI LILLY | Selective Estrogen Receptor Degraders |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2030 |
Drugs and Companies using IMLUNESTRANT TOSYLATE ingredient
NCE-1 date: 25 September, 2029
Market Authorisation Date: 25 September, 2025
Dosage: TABLET
More Information on Dosage
INLURIYO family patents
